Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted?

Gynecologic Oncology

Volumn 144, Issue 2, 2017, Pages 238-240

  Narod, Steven ^a   Sopik, Victoria ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CYTOREDUCTIVE SURGERY; EDITORIAL; FEMALE; HUMAN; MEDICAL SOCIETY; MINIMAL RESIDUAL DISEASE; OVARY CANCER; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; NEOADJUVANT THERAPY; ONCOLOGY; OVARY TUMOR; UNITED STATES;

CARCINOMA, OVARIAN EPITHELIAL; FEMALE; HUMANS; MEDICAL ONCOLOGY; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; UNITED STATES;

EID: 85009062660     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.11.046     Document Type: Editorial

References (12)

1. [1] Wright, A.A., Bohlke, K., Armstrong, D.K., et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol., 2016 (pii: JCO686907).
2. [2] Vergote, I., Trope, C.G., Amant, F., et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363 (2010), 943–953.
3. [3] Kehoe, S., Hook, J., Nankivell, M., et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386 (2015), 249–257.
4. [4] Onda, T., Satoh, T., Saito, T., et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan clinical oncology group study JCOG0602. Eur. J. Cancer 64 (2016), 22–31.
5. [5] Fagotti, A., Ferrandina, G., Vizzielli, G., et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur. J. Cancer 59 (2016), 22–33.
6. [6] Narod, S., Can advanced-stage ovarian cancer be cured?. Nat. Rev. Clin. Oncol. 13 (2016), 255–261.
7. [7] Stewart, J.M., Tone, A.A., Jiang, H., et al. The optimal time for surgery in women with serous ovarian cancer. Can. J. Surg. 59 (2016), 223–232.
8. [8] Chi, D.S., Bristow, R.E., Armstrong, D.K., Karlan, B.Y., Is the easier way ever the better way?. J. Clin. Oncol. 29 (2011), 4073–4075.
9. [9] Rosen, B., Laframboise, S., Ferguson, S., et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol. Oncol. 134 (2014), 462–467.
10. [10] Meyer, L.A., Cronin, A.M., Sun, C.C., et al. Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. J. Clin. Oncol., 2016 (pii: JCO681239).
11. [11] Tewari, D., Java, J., Salani, R., et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 33 (2015), 1460–1466.
12. [12] Horowitz, N., Miller, A., Rungruang, B., et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J. Clin. Oncol. 33 (2015), 937–943.